Study Title

Phase II Study of Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy

Study Details

Description:

Male adults with a confirmed diagnosis of prostate adenocarcinoma who meet criteria for localized high risk prostate cancer according to the NCCN guidelines and who are eligible for prostatectomy will be invited to participate. Criteria for high-risk prostate cancer include patients with preoperative prostate biopsy score of Gleason 8 (GS8) (Grade group 4 [GG4]) or higher. Patients also need to have a positive PSMA scan on 68-Ga-PSMA-11 PET/CT scan.

Sponsor:

Hackensack Meridian Health

Contacts:

Oncology Clinical Research Referral Office

oncologyresearchreferral@hmhn.org

551-996-1777

Drug Details

Lu-177-PSMA-617
Isotope(s):
    LUTETIUM-177
    Radioisotope: Lu-177
    Theranostic Role: Therapeutic Agent & SPECT Imaging
    T1/2 (Half-Life): 6.7 Days
    Decay Mode: BETA, GAMMA
    Energy: Eβeta max 497 keV, Gamma 113-208 keV
    Range: In Tissue: 0.25-2mm
    Decay Daughters: Hf177
    Status: FDA Approvals: PLUVICTO® (2022), LUTATHERA® (2017)
  • LUTETIUM-177
Target(s):
  • PSMA
Chelator: DOTA
XCancer

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468